Why the study?
Does TAVI reduce mortality or adverse events compared to SAVR in patients with aortic valve stenosis?
Does TAVI reduce mortality or adverse events compared to SAVR in patients with aortic valve stenosis?
The choice between TAVI and SAVR should be individualized due to similar mortality but differing adverse event profiles.
Supports individualized TAVI or SAVR selection by adverse event profiles; confirms similar mortality in aortic stenosis.
Given similar mortality risks but different patterns of adverse events, the choice between TAVI and SAVR remains an individual one.
No takes yet. Share an insight, caveat, or question.
Wagner et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: